SCHEMBL6700959

SCHEMBL6700959

O=C(O)c1ccccc1Cc1ccccc1NC(=O)C(CC1CCC1)c1cccc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.66
SLC16A3 O15427 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ACP3 P15309 1/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PPM1D O15297 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EPHX1 P07099 1/20 0.36
TSHR P16473 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6699480 0.96 PTGER4 (0.68) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL14559121 0.85 PTGER4 (0.74) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL6700544 0.84 PTGER4 (0.53) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL5352537 0.84 PTGER4 (0.77) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL14569753 0.84 PTGER4 (0.73) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL6700645 0.83 PTGER4 (0.72) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL6700401 0.82 PTGER4 (0.70) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL5353199 0.82 PTGER4 (0.77) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL5347418 0.82 PTGER4 (0.74) PTGER4SLC16A3MEN1KMT2AKDM4E
SCHEMBL5365416 0.81 PTGER4 (0.72) PTGER4SLC16A3MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040002493-A1 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-01-01 US claimed
EP-1314719-A1 BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP claimed
US-20040002493-A1 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-01-01 US disclosed
EP-1314719-A1 BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002493-A1 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient PTGER1, PTGER4, PTGES PTGER4 2/4885SLC16A3 1957/4885MEN1 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.